Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
News provided by
Share this article
Share this article
SAN FRANCISCO and SUZHOU, China, June 6, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent , HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the results of the Phase 1 study in Chinese patients with advanced solid tumors were released today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2021.
This is a Phase 1 study to evaluate the pharmacokinetic (PK), pharmacodynamic (PD) and safety of pemigatinib in Chinese patients (pts) with advanced malignancy. Moreover, potential efficacy of pemigatinib was explored in a broad spectrum of fibroblast growth factor receptor (FGFR) alteration in variety of cancer types. 12
A further wave of exciting cancer breakthroughs were unveiled at the American Society for Clinical Oncology s annual meeting. Here, we outline a handful of the most remarkable discoveries.
New hope for cancer patients after UK drugs trial walesonline.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from walesonline.co.uk Daily Mail and Mail on Sunday newspapers.